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The antitumor activity of umbelliferone in human renal cell 
carcinoma via regulation of the p110γ catalytic subunit of PI3Kγ
Umbelliferone exhibits extensive pharmacological activity, 
including anti-immunomodulatory, anti-inflammatory and 
antigenotoxicity activities. However, its antitumor properties 
still remain unclear in human renal cell carcinoma (RCC) 
cells. Our results have revealed that treatment of human RCC 
cells (786-O, OS-RC-2, and ACHN) with umbelliferone redu-
ced cell proliferation in a concentration-dependent manner 
and induced dose-dependent apoptotic events. In addition, 
cell cycle analysis determined that umbelliferone treatment 
induced cell cycle arrest in the G1 phase in a dose-dependent 
manner. Furthermore, western blotting analysis showed a 
dose-dependent decrease in Ki67, MCM2, Bcl-2, CDK2, Cy-
clinE1, CDK4, and CyclinD1 and a dose-dependent increase in 
Bax in RCC cells cultured with umbelliferone. Similarly, um-
belliferone exhibited a dose-dependent reduction of p110γ 
when using western blotting analyses. Taken together, these 
results provide an insight into the pharmacology regarding 
the potential application of umbelliferone, which contributes 
to cell death by decreasing p110γ protein expression.
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Kidney cancer accounts for approximately 5 % of all new cancer diagnoses. Renal cell 
carcinoma (RCC), which arises from renal epithelium, is the most common form of kidney 
cancer (1). Unfortunately, unlike other solid tumours, RCC is still refractory to standard 
cytotoxic chemotherapy and most patients eventually develop resistance after receiving 
one or more therapeutic agents (2). Thus, it is urgent to develop new and improved antitu-
mor drugs, particularly drugs of natural origin.
Umbelliferone, also known as 7-hydroxycoumarin, is a polyphenolic component 
found in fruits, vegetables, roots of plants and flowers (e.g., golden apple, carrot, coriander, 
garden angelica, mouse-ear hawkweed and pharbitis nil) (3). It has multiple functions, 







1 Department of Urologic Surgery, 
Ningbo Urology and Nephrology 
Hospital, Ningbo 315000, China
2 Laboratory of Kidney Carcinoma, 
Urology and Nephrology Institute of 
Ningbo University, Ningbo 315000 
China
3 Ningbo University, School of 
Medicine, Ningbo 315211, China
Accepted August 18, 2018 
Published online September 18, 2018
* Correspondence; e-mail: nbuurology@126.com
112
X. Wang et al.: The antitumor activity of umbelliferone in human renal cell carcinoma via regulation of the p110γ catalytic subunit 
of PI3Kγ, Acta Pharm. 69 (2019) 111–119.
 
Phosphoinositide 3-kinases (PI3Ks), a family of dual-specificity signalling enzymes 
(5), generate lipid second messengers that regulate different aspects of cell biology, such as 
cell growth, survival, motility and metabolism. Mammals have eight isoforms of PI3Ks, 
which have been divided into three classes, class I, II, and III PI3Ks. Thus far, class I PI3Ks 
are the best understood and most studied class because they are known to have a great 
effect on cancer (6). On the basis of a strong association with regulatory subunits, catalytic 
subunits of class I PI3Ks are subdivided into class IA and class IB PI3Ks. The only class IB 
PI3K member, p110γ, binds to the regulatory subunit p101 rather than p85. Some evidence 
has shown that p110γ is also activated by G-proteins in the absence of p101 in vitro and in 
vivo (7). Unexpectedly, PI3Kγ signalling has been reported to activate C/EBPβ activation 
via mTor and Akt suppression of NFκB activation and subsequently promote immunosup-
pression during tumour growth and inflammation in mouse models of cancer (8). How-
ever, the role of the p110γ catalytic subunit of PI3Kγ in human cancer, particularly in hu-
man RCC, has yet to be identified. Therefore, the present study mainly aims to evaluate the 
cytotoxic potential of umbelliferone in vitro, using three human RCC cell lines, which en-
able the identification of umbelliferone and its effective inhibition of RCC by p110γ.
EXPERIMENTAL
Cell lines and cell culture
786-O and ACHN cells (human RCC cell lines) were obtained from the American Type 
Culture Collection (USA). OS-RC-2 cells (human RCC cell line) were purchased from the Cell 
Bank of the Chinese Academy of Sciences, Shanghai, China. 786-O and OS-RC-2 cells were 
maintained in RPMI 1640 medium (HyClone, UT, USA) containing 10 % FBS (Shanghai Ex-
Cell Biology, Inc., China). ACHN cells were maintained in Dulbecco’s modified Eagle’s me-
dium (HyClone, USA) containing 10 % FBS (Shanghai ExCell Biology, Inc., China). All cell 
lines were grown at 37 °C in a humidified atmosphere and in the presence of 5 % CO2.
MTS assay
All cell lines were incubated in 96-well plates (Corning Inc., USA) at a density of 5 × 103 
cells/well in RPMI-1640 or DMEM with 10 % FBS. After 24 h, the cells were incubated with 
0, 5, 25, 50, 100 or 150 μmol L–1 of umbelliferone for 0, 24, 48 or 72 h at 37 °C in 5 % of CO2. 
Next, 20 μL of CellTiter 96® Aqueous One Solution Reagent (MTS, PROMEGA, USA) was 
added to each well and the samples were incubated at 37 °C for 3 h. After that, the absorbance 
was measured at 490 nm using a spectrophotometer (Thermo Multiskan GO, USA).
Cell apoptosis detection by flow cytometry
According to the manufacturer’s instructions, cell apoptosis was tested using an 
Apoptosis Detection kit (AP101-30, MultiSciences (Lianke) Biotechnology Corporate 
 Limited, China). Briefly, all cell lines were treated with 0, 5, 25, 50, 100 or 150 μmol L–1 of 
umbelliferone. After 48 h, cells (1–5 × 105 cells) were collected, washed with PBS, resus-
pended in 500 μL of 1× Binding Buffer, and then stained with 5 μL of Annexin V-FITC and 
10 μL of PI for 5 min in the dark, and subsequently analysed using a FACScan flow cyto-
meter (BD Biosciences, USA).
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Cell cycle analysis
All cell lines were treated with a wide range of umbelliferone concentrations (0, 5, 25, 
50, 100 or 150 μmol L–1) for 48 h. Subsequently, the cell cycle was measured using a cell 
cycle detection kit (CCS012, MultiSciences (Lianke) Biotechnology Corporate Limited, 
China) according to the manufacturer’s instructions. Briefly, cells (2–10 × 105 cells) were 
collected, washed with PBS, and stained with 1 mL of DNA staining solution and 10 μL of 
permeabilization solution at room temperature for 30 min; flow cytometric analysis was 
then performed by FACScan flow cytometry (BD Biosciences, USA).
Western blot analysis
Cultured cells were lysed and protein was extracted using High-efficiency RIPA lysis 
buffer (Solarbio, China) after umbelliferone treatment (0, 5, 25, 50, 100 or 150 μmol L–1) as 
described above for 48 h. Equal amounts of protein were loaded onto SDS-PAGE before 
transfer onto PVDF membranes (0.2 μm, #162-0177 Bio-Rad, USA). After blocking with 5 % 
non-fat dry milk, the membranes were incubated with specific primary antibodies over-
night at 4 °C. The following antibodies were used: anti-MCM2 (#12079), Cyclin E1 (#20808), 
Bax (#5023), Bcl-2 (#15071), phosphoinositide 3-kinase p110γ (#4252S), CDK2 (#2546S), CDK4 
(#2906S), β-actin (#8457), GAPDH (#5174) (Cell Signaling Technology, USA, dilution 1:1,000), 
Cyclin D1 (PB0403) (Wuhan Boster Biological Technology, Ltd., China, dilution 1:1,000), 
and anti-Ki67 antibody (ab15580) (Abcam, UK, dilution 1:1,000). Secondary antibodies in-
cluded goat anti-rabbit (BA1054) or goat anti-mouse (BA1050) IgG-HRP (Wuhan Boster 
Biological Technology, Ltd., China, dilution 1:5,000). Signals were detected by enhanced 
chemiluminescence (ECL) reagent (Beyotime). Densitometric analysis of proteins was per-
formed using the Tanon GIS version 4.1.2 software (Tanon Science and Technology Co., 
Ltd., China).
Statistical analysis
Results were expressed as the mean ± SD of three representative independent experi-
ments. Statistical analysis was performed using one-way ANOVA with SPSS 18.0 software. 
p < 0.05 was considered to be statistically significant compared to 0 μmol L–1 umbelliferone.
RESULTS AND DISCUSSION
Cytotoxic effect of umbelliferone against human RCC cells
The effects of umbelliferone on the growth of human malignant cell lines in vitro have 
demonstrated umbelliferone as a potent cytotoxic and cytostatic agent and as a more po-
tent derivative compared to coumarins (9).
To detect the effect of umbelliferone on human RCC, we first examined the changes 
in cell proliferation in human RCC cells treated with umbelliferone. As shown in Fig. 1, 
treatment of cells with umbelliferone at concentrations of 50, 100 and 150 μmol L–1 caused 
a gradual decrease in cell proliferation. This decrease continued following 48 and 72 h 
exposure, which appeared to be concentration-dependent. In addition, decreased cell pro-
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liferation was observed in response to umbelliferone at the 72 h time-point in 786-O cells 
and at the 48 and 72 h time-points in ACHN cells, but no change was observed at the 
studied time-points in OS-RC-2 cells. These observations indicated that human RCC had 
a concentration-dependent effect in response to umbelliferone; however, the time depen-
dence was not obvious.
Umbelliferone increased cell apoptosis in human RCC
Annexin V/FITC staining showed a clear induction of apoptosis in a dosedependent 
manner in 786-O, OS-RC-2 and ACHN cells. With an increase in umbelliferone concentra-
tion, the proportions of early apoptotic human RCC cells continuously increased (Fig. 2). 
Fig. 1. 786-O, OS-RC-2 and ACHN cell proliferation after incubation with umbelliferone in a gradient 
concentration (0–150 μmol L–1) at 0, 24, 48 and 72 h. Data are presented as the mean ± SD from three 
independent experiments. * p < 0.05, ** p < 0.01 vs. 0 μmol L–1 treatment.
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Umbelliferone also exhibited significant anticancer effects by inducing dose-dependent 
apoptosis in HepG2 cells (3). These results indicated that umbelliferone promoted cell 
apoptosis in cancer in a concentration-dependent manner.
Umbelliferone arrested cell cycle in G1 phase in human RCC
In addition, umbelliferone regulated cell death via DNA damage and arrest in the G0/
G1 phase of the cell cycle and had anticancer effects in a human oral carcinoma cell line 
(10). However, Jose Sullivan Lopez-Gonzalez et al. found that umbelliferone suppressed 
cell growth by arresting the cell cycle in the G1 phase, but the apoptosis of lung carcinoma 
cells was not related to intra-nucleosomal DNA fragmentation in all lung carcinoma cell 
lines (11). In the current study, we found that following an increase in umbelliferone con-
centration, the percentage of cells in the S and G2 phases was gradually reduced and the 
proportion of cells in the G1 phase was continuously increased in 786-O, OS-RC-2 and 
ACHN cells (Fig. 3). Therefore, we proposed that umbelliferone induced G1 phase arrest 
in a variety of cancers and exerted an effect on their proliferation and apoptotic pattern.
Umbelliferone induces the expression of proteins related to cell proliferation, apoptosis 
and cell cycle
Moreover, umbelliferone decreased the expression of cyclin D1 protein in the human 
lung adenocarcinoma cell line A-427(12). An increase in Bax protein and a decrease in Bcl-2 
protein were also observed in umbelliferone-pretreated A427 cells. Furthermore, C. M. Eli-
Fig. 2. 786-O, OS-RC-2 and ACHN cell apoptosis after 48 h incubation with 0, 5, 25, 50, 100 and 150 
μmol L–1 of umbelliferone. Dot-plot of Annexin-V-fluorescein vs. PI, early apoptotic cells (%) are lo-
calised in the lower right quadrant. Data are shown as the mean ± SD from three independent ex-
periments. * p < 0.05, ** p < 0.01 vs. 0 μmol L–1 treatment.
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nos-Ba et al. concluded that umbelliferone was a more potent inhibitor of cancer cell prolife-
ration compared to coumarin and exhibited marked effects on oncoprotein expression (13). 
Thus, we detected expression of the proliferation biomarkers, Ki67 and MCM2; pro-apoptotic 
protein Bax; anti-apoptotic protein Bcl-2; and several key cell cycle control proteins, includ-
ing CDK2, CyclinE1, CDK4, and CyclinD1, using western blotting analysis. It was clear that 
umbelliferone effectively up-regulated the expression of Bax protein and down-regulated 
the expression of Ki67, MCM2, Bcl-2, CDK2, CyclinE1, CDK4, and CyclinD1 protein compared 
to cells treated with 0 μmol L–1 umbelliferone, further confirming the inhibitory effect of 
umbelliferone on proliferation regulation, the enhanced effect of umbelliferone on apoptosis 
induction and the arrested effect of umbelliferone on cell cycle in the G1 phase (Fig. 4). With 
regard to these proteins, umbelliferone treatment resulted in a dose-dependent regulation 
in human RCC cells, which was consistent with the above results.
P110γ contributes to umbelliferone-induced human RCC cell proliferation,  
apoptosis and cell cycle
In normal cells, PI3Ks activity is closely controlled by internal signals, for example, 
PTEN, but it has been observed that the development of 1/3 of human cancers is related to 
an imbalance of the PI3K signalling pathway (14). Researchers have found that inhibition 
Fig. 3. Cell cycle distributions of umbelliferone treated 786-O, OS-RC-2 and ACHN cells with various 
concentrations (0, 5, 25, 50, 100 and 150 μmol L–1) for 48 h. Histograms indicate the number of the 
channel (horizontal axis) against DNA content (vertical axis). Data are shown as the mean ± SD from 
three independent experiments. * p < 0.05, ** p < 0.01 vs. 0 μmol L–1 treatment.
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of PI3K expression enhanced Bcl-2-dependent apoptosis in RCC (15). To further explore 
whether p110γ has an important function in human RCC induced by umbelliferone, we 
observed the expression of p110γ protein.
Fig. 4. Concentration-dependent inhibition of Ki-67, MCM2, Bcl-2, Bax, CDK2, CyclinE1, CDK4, Cy-
clinD1 protein expression in 786-O, OS-RC-2 and ACHN cells by umbelliferone. Data are shown as 
the mean ± SD from three independent experiments. * p < 0.05, ** p < 0.01 vs. 0 μmol L–1 treatment.
Fig. 5. Concentration-course inhibition of PI3K p110γ by umbelliferone in human RCC cells: a) Western 
blotting analyses were performed to detect the level of p110γ in human RCC cells and HK-2; b) 786-O, 
OS-RC-2 and ACHN cells were incubated with increasing concentrations of umbelliferone for 48 h. 
p110γ protein expression levels were analysed by western blot using their corresponding specific anti-
bodies. The same lysates were then probed for β-actin as a normalisation control. Data are shown as 
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We found that the expression of p110γ was upregulated in human RCC cell lines, 786-
O, OS-RC-2 and ACHN, compared to HK-2 (Fig. 5a). Moreover, we observed a significant 
concentration-dependent decrease in p110γ. At 50 μmol L–1, umbelliferone resulted in sus-
tained inhibition in the expression of p110γ (Fig. 5b). This finding was consistent with 
umbelliferone-regulated Ki67, MCM2, Bax, Bcl-2, CDK2, CyclinE1, CDK4, and CyclinD1 
expression in these cell lines.
CONCLUSIONS
Taken together, we propose that umbelliferone regulated the expression of prolifera-
tion-related proteins, apoptosis-related proteins and cell cycle control proteins via p110γ in 
human RCC cells and further regulated cell cycle arrest, inhibited tumour cell prolife ra tion 
and induced apoptosis in vitro. In conclusion, the suppressive activity of umbelliferone in 
human RCC is mediated by p110γ. Importantly, umbelliferone might be a potential medi-
cine in the treatment of human RCC. However, p110γ most likely exhibits more complex 
mechanisms in its contribution to cancer and the function of p110γ requires further exten-
sive study.
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